Page 17 - எங்களுக்கு தேசிய நிறுவனம் ஆஃப் ஆரோக்கியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

-in -class SK2 selective inhibitor targeting multiple indications with positive Phase 2 COVID-19 data and an ongoing Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii) RHB-107 (upamostat), a serine protease inhibitor in a U.S. Phase 2/3 study as treatment for symptomatic COVID-19, and targeting multiple other cancer and inflammatory gastrointestinal diseases; (iv) RHB-104, with positive results from a first Phase 3 study for Crohn s disease; (v) RHB-102 (Bekinda ®), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; and (vi) RHB- 106, an encapsulated bowel preparation. More information about the Company is available at www.redhillbio.com / https://twitter.com/RedHillBio.           

South africaUnited kingdomSouth africanWilliam seversonDelta indianAmber fennellBryan gibbsRedhill biopharmaAdi frishOpaganib yelivaReza fathiUs national institute of healthRedhill biopharma ltdResources for the centerExchange commissionUniversity of louisville center